Yahoo Web Search

  1. Yahoo Finance Results

  2. I would now like to introduce your host for today's conference, Sarah Carmody, Senior Director of Investor Relations. Following them -- our remarks, we will open the call to questions.

  3. Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?

    Zacks via Yahoo FinanceOct 31 20:18 PM

    Mylan N.V. MYL is scheduled to report third-quarter 2018 results on Nov. 5, after the market closes. The company’s performance has been dismal so far, having missed earnings estimates ...

  4. (after the market close) Neurocrine Biosciences, Inc. NASDAQ: NBIX) (after the market close) Dynavax Technologies Corporation (NASDAQ: DVAX) (after the market close) PTC Therapeutics, ...

  5. Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 5) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...

  6. 3 Hammered Healthcare Stocks to Buy Now

    Motley Fool via Yahoo FinanceNov 01 12:54 PM

    Align Technology, Inc. (NASDAQ: ALGN), Celgene Corporation (NASDAQ: CELG), and Ligand Pharmaceuticals Inc. (NASDAQ: LGND) have delivered less than thrilling news recently ...

  7. 9 High-Risk Stocks to Buy for Massive Rewards

    InvestorPlace via Yahoo FinanceNov 06 20:20 PM

    Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet ...

  8. Mylan and Theravance's COPD treatment gets FDA approval

    Reuters via Yahoo FinanceNov 09 21:10 PM

    Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems. The ...

  9. Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3

    Zacks via Yahoo FinanceNov 09 20:25 PM

    The increase in product revenues was primarily due to non-recurring deduction of a $5-million contractual amount in 2017, which was offset by lower net sales of Glatopa, driven by Mylan ...

  10. This week Lilly LLY and AstraZeneca AZN released their third-quarter 2018 results. Pfizer PFE gained FDA approval for a new cancer medicine, its third cancer drug approval in less than two months ...

  11. Theravance Biopharma, Inc. TBPH incurred third-quarter 2018 loss of $1.10 per share, narrower than the Zacks Consensus Estimate of a loss of $1.18 and the year-ago loss of $1.27. Moreover ...